Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Published
Journal Article (Letter)
Full Text
Duke Authors
Cited Authors
- Mistry, PK; Balwani, M; Baris, HN; Turkia, HB; Burrow, TA; Charrow, J; Cox, GF; Danda, S; Dragosky, M; Drelichman, G; El-Beshlawy, A; Fraga, C; Freisens, S; Gaemers, S; Hadjiev, E; Kishnani, PS; Lukina, E; Maison-Blanche, P; Martins, AM; Pastores, G; Petakov, M; Peterschmitt, MJ; Rosenbaum, H; Rosenbloom, B; Underhill, LH; Cox, TM
Published Date
- July 2018
Published In
Volume / Issue
- 71 /
Start / End Page
- 71 - 74
PubMed ID
- 29680197
Pubmed Central ID
- 29680197
Electronic International Standard Serial Number (EISSN)
- 1096-0961
Digital Object Identifier (DOI)
- 10.1016/j.bcmd.2018.04.001
Language
- eng
Conference Location
- United States